PDD Holdings Inc. American Depositary Shares vs Personalis Inc. Common Stock — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $80.34 (market cap $116.66B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 69× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is trading nearer its 52-week high, PDD Holdings Inc. American Depositary Shares nearer its low. Which is the better fit depends on your goals.
| PDD | PSNL | |
|---|---|---|
Market Cap | $116.66B | $1.69B |
Volume | 9,095,378 | 3,817,236 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $18.38 |
52-Week Low | $73.30 | $5.04 |
Enterprise Value | $49.19B | $1.52B |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
PDD Holdings trades at $81.96, up 1.29% with a bullish technical signal despite recent earnings volatility. The stock shows strong fundamentals with a P/E of 8.81 and robust profitability margins (net income margin 20.43%). Recent news highlights investor attention and the company's major investment cycle while facing regulatory and competitive pressures.
The outlook remains cautiously optimistic with a $99.13 consensus price target, though risks include trade policy impacts and execution challenges from PDD's shift to an asset-heavy model. Earnings misses in recent quarters and moderating revenue growth warrant close monitoring for sustained investor confidence.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →